Intravenous thrombolytic therapy for acute ischemic stroke
- 1 April 1998
- journal article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 103 (4) , 221-231
- https://doi.org/10.3810/pgm.1998.04.457
Abstract
The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be restricted to a carefully selected patient population. Treatment must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.Keywords
This publication has 7 references indexed in Scilit:
- PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery StrokeStroke, 1998
- Streptokinase for Acute Ischemic Stroke With Relationship to Time of AdministrationJAMA, 1996
- Thrombolytic Therapy with Streptokinase in Acute Ischemic StrokeNew England Journal of Medicine, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic strokeThe Lancet, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995
- Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.Stroke, 1994